EuroBiotech—More articles of note

(NS Newsflash/CC BY 2.0)

> Innate Pharma agreed to trial anti-C5aR monoclonal antibody IPH5401 in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi. The phase 1/2 trial will assess the effect of the combination in patients with certain types of solid tumors. Statement

> BerGenBio posted data from phase 2 trials that are administering its AXL inhibitor in combination with Merck’s Keytruda. Release 

> Helsinn Healthcare joined with Scientific Centre of Monaco to develop pharmacological inhibitors in kidney cancer. Release 


Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

> Sanofi filed for European approval of a sleeping sickness treatment. The French pharma worked on the therapy with the Drugs for Neglected Disease Initiative. Statement

> Affimed shared data from a trial that tested NK cell engager candidate AFM13 in combination with Keytruda. Statement

Suggested Articles

Sarepta will negotiate a warning for golodirsen rather than carry out more studies. But the implications of the rejection range beyond golodirsen.

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.

The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.